{
    "organizations": [],
    "uuid": "d5492740a6fb126468bb4bff1e460a70ae0a5013",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-isofol-medical-successful-regulato/brief-isofol-medical-successful-regulatory-meeting-with-fda-idUSFWN1PB1DI",
    "ord_in_thread": 0,
    "title": "BRIEF-Isofol Medical: Successful Regulatory Meeting With FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 17 (Reuters) - ISOFOL MEDICAL AB:\n* SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA AND PHASE 3 PROGRAM FOR MODUFOLIN® AGREED\n* ‍HAS HAD SUCCESSFUL REGULATORY MEETING WITH US FDA, IMPORTANT MILESTONE IN REGULATORY PROCESS​\n* ‍PHASE III STUDY, ISO-CC-007, IS EXPECTED TO BE COMPLETED BY 2020/2021​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-17T15:19:00.000+02:00",
    "crawled": "2018-01-18T16:24:52.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "isofol",
        "medical",
        "ab",
        "successful",
        "meeting",
        "fda",
        "phase",
        "program",
        "agreed",
        "successful",
        "regulatory",
        "meeting",
        "u",
        "fda",
        "important",
        "milestone",
        "regulatory",
        "iii",
        "study",
        "expected",
        "completed",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}